• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Solventum Corporation

    3/21/25 4:13:55 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email
    DEFA14A 1 solventumcorporationvcvn.htm DEFA14A solventumcorporationvcvn
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☑ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 SOLVENTUM CORPORATION (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): ☑ No fee required ☐ Fees paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


     
    Your Vote Counts! SOLVENTUM CORPORATION 3M CENTER BUILDING 275-6W-02 ST. PAUL, MN 55144-1000 SOLVENTUM CORPORATION You invested in SOLVENTUM CORPORATION and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on April 30, 2025. Vote Virtually at the Meeting* April 30, 2025 9:00 AM EDT Virtually at: www.virtualshareholdermeeting.com/SOLV2025 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V67801-P24831 Get informed before you vote View the Notice and Proxy Statement, Annual Report and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 16, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. 2025 Annual Meeting Vote by April 29, 2025 11:59 PM ET. For shares held in a Plan, vote by April 27, 2025 11:59 PM ET.


     
    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V67802-P24831 1. Election of Directors Nominees: 1a. Glenn A. Eisenberg For 1b. Elizabeth A. Mily For 1c. John H. Weiland For 1d. Amy A. Wendell For 2. Advisory vote to approve executive compensation For 3. Advisory vote on frequency of advisory vote to approve executive compensation 1 Year 4. Ratification of the appointment of PwC as Solventum’s independent registered public accounting firm for the fiscal year ending December 31, 2025 For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.


     
    Get the next $SOLV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    12/4/2024$70.00Neutral
    Mizuho
    10/8/2024$82.00Buy
    Stifel
    10/7/2024$71.00Neutral
    Piper Sandler
    9/26/2024Peer Perform
    Wolfe Research
    9/5/2024Neutral
    BTIG Research
    6/24/2024Hold
    Argus
    5/30/2024$54.00Sell
    Goldman
    More analyst ratings

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Alban Carlos

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:38:20 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Cox Carrie Smith

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:34:40 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Devore Susan D.

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:31:57 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Financials

    Live finance-specific insights

    See more
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

      ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646

      4/17/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance

      Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3%GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41Generated $219 million in cash from operations; free cash flow of $92 millionIntroduces full-year 2025 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 27, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter ended December 31, 2024. "Solventum executed another quarter of solid performance, enabling us to deliver full year 2024 at the high end of our ex

      2/27/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Participate in the 2025 BofA Securities Health Care Conference

      ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025, beginning at approximately 2:20 p.m. PST in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest chal

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

      ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646

      4/17/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    See more
    • Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

      BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

      2/11/25 8:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

      Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

      1/8/25 6:30:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

      ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

      10/10/24 9:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/12/24 5:47:11 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/4/24 1:47:43 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Solventum Corporation

      10-Q - Solventum Corp (0001964738) (Filer)

      5/9/25 12:24:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Solventum Corp (0001964738) (Filer)

      5/8/25 4:13:51 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Solventum Corp (0001964738) (Filer)

      5/2/25 4:12:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Solventum Corporation with a new price target

      Mizuho initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $70.00

      12/4/24 7:49:27 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Solventum Corporation with a new price target

      Stifel initiated coverage of Solventum Corporation with a rating of Buy and set a new price target of $82.00

      10/8/24 7:35:48 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on Solventum Corporation with a new price target

      Piper Sandler initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $71.00

      10/7/24 8:25:35 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care